Five Prime Therapeutics Reports Third Quarter 2015 Results and Provides Business Update
Established license and collaboration agreement with Bristol-Myers Squibb for FPA008: $1.74 billion in upfront and milestone payments, double-digit royalties, and ability to continue development in PVNS and with Five Prime oncology candidates Expanded …